Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1

Molecular Psychiatry

Volumn 21, Issue 11, 2016, Pages 1613-1623

  Fujitsuka, N ^a,b   Asakawa, A ^a   Morinaga, A ^a   Amitani, M S ^a   Amitani, H ^a   Katsuura, G ^a   Sawada, Y ^c   Sudo, Y ^c   Uezono, Y ^c   Mochiki, E ^d   Sakata, I ^e   Sakai, T ^e   Hanazaki, K ^f   Yada, T ^g   Yakabi, K ^d   Sakuma, E ^h   Ueki, T ^h   Niijima, A ⁱ   Nakagawa, K ^j   Okubo, N ^j   Takeda, H ^j,k   Asaka, M ^l   Inui, A ^a   more..

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Tsumura Research Laboratories   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e SAITAMA UNIVERSITY   (Japan)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

ⁱ NIIGATA UNIVERSITY   (Japan)

^j HOKKAIDO UNIVERSITY   (Japan)

^k HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^l HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

(DEXTRO LYSINE3) GROWTH HORMONE RELEASING PEPTIDE 6; ATRACTYLODIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GHRELIN; GHRELIN RECEPTOR; GHRELIN RECEPTOR 1A; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; KAMPO; RIKKUNSHITO; SIRTUIN 1; UNCLASSIFIED DRUG; HERBACEOUS AGENT; LIU-JUN-ZI-TANG;

AGING; ANIMAL EXPERIMENT; APPETITE; ARTICLE; ATROPHY; CALCIFICATION; CALORIC RESTRICTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HYPOTHALAMUS; IN VITRO STUDY; LIFESPAN; MICROGLIA; MOUSE; MOUSE STRAIN; MUSCLE CELL; MYOCARDIAL DISEASE; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE ACCELERATED MOUSE; SURVIVAL; TRADITIONAL MEDICINE; TREATMENT FAILURE; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; DISEASE MODEL; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGING; ANIMALS; CALORIC RESTRICTION; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; GHRELIN; HYPOTHALAMUS; MICE; MICE, INBRED ICR; RECEPTORS, GHRELIN; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84990054119     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.220     Document Type: Article

References (60)

1. Heemels MT. Ageing. Nature 2010; 464: 503.
2. Maxmen A. Calorie restriction falters in the long run. Nature 2012; 488: 569.
3. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012; 11: 443-461.
4. Toorie AM, Nillni EA. Minireview: central Sirt1 regulates energy balance via the melanocortin system and alternate pathways. Mol Endocrinol 2014; 28: 1423-1434.
5. Satoh A, Imai S. Hypothalamic Sirt1 in aging. Aging (Albany NY) 2014; 6: 1-2.
6. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001; 2: 551-560.
7. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
8. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
9. Fujino K, Inui A, Asakawa A, Kihara N, Fujimura M, Fujimiya M. Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. J Physiol 2003; 550: 227-240.
10. Kishimoto I, Tokudome T, Hosoda H, Miyazato M, Kangawa K. Ghrelin and cardiovascular diseases. J Cardiol 2012; 59: 8-13.
11. Dezaki K, Hosoda H, Kakei M, Hashiguchi S, Watanabe M, Kangawa K et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 2004; 53: 3142-3151.
12. Wang Y, Nishi M, Doi A, Shono T, Furukawa Y, Shimada T et al. Ghrelin inhibits insulin secretion through the AMPK-UCP2 pathway in beta cells. FEBS Lett 2010; 584: 1503-1508.
13. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 2005; 288: E486-E492.
14. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004; 279: 12005-12008.
15. Kohno D, Sone H, Minokoshi Y, Yada T. Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem Biophys Res Commun 2008; 366: 388-392.
16. Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, Friedman JM et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 2008; 454: 846-851.
17. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-1060.
18. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry 2011; 1: e23.
19. Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cachexia and herbal medicine: perspective. Curr Pharm Des 2012; 18: 4865-4888.
20. Takeda H, Sadakane C, Hattori T, Katsurada T, Ohkawara T, Nagai K et al. Rik-kunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008; 134: 2004-2013.
21. Nahata M, Saegusa Y, Sadakane C, Yamada C, Nakagawa K, Okubo N et al. Administration of exogenous acylated ghrelin or rikkunshito, an endogenous ghrelin enhancer, improves the decrease in postprandial gastric motility in an acute restraint stress mouse model. Neurogastroenterol Motil 2014; 26: 821-831.
22. Tsubouchi H, Yanagi S, Miura A, Mogami S, Yamada C, Iizuka S et al. Rikkunshito ameliorates cachexia associated with bleomycin-induced lung fibrosis in mice by stimulating ghrelin secretion. Nutr Res 2014; 34: 876-885.
23. Kitagawa H, Munekage M, Matsumoto T, Sadakane C, Fukutake M, Aoki K et al. Pharmacokinetic profiles of active ingredients and its metabolites derived from rikkunshito, a ghrelin enhancer, in healthy Japanese volunteers: a cross-over, randomized study. PLoS One 2015; 10: e0133159.
24. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
25. Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009; 61: 430-481.
26. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp Gerontol 1997; 32: 105-109.
27. Camina JP. Cell biology of the ghrelin receptor. J Neuroendocrinol 2006; 18: 65-76.
28. Fusco S, Ripoli C, Podda MV, Ranieri SC, Leone L, Toietta G et al. A role for neuronal cAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction. Proc Natl Acad Sci USA 2012; 109: 621-626.
29. Holst B, Schwartz TW. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci 2004; 25: 113-117.
30. Conconi MT, Nico B, Guidolin D, Baiguera S, Spinazzi R, Rebuffat P et al. Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. Peptides 2004; 25: 2179-2185.
31. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 2011; 589: 4545-4554.
32. Ewart MA, Kennedy S. AMPK and vasculoprotection. Pharmacol Ther 2011; 131: 242-253.
33. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005; 2: 21-33.
34. Omar B, Zmuda-Trzebiatowska E, Manganiello V, Goransson O, Degerman E. Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal 2009; 21: 760-766.
35. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374.
36. Schwartz MW, Dallman MF, Woods SC. Hypothalamic response to starvation: implications for the study of wasting disorders. Am J Physiol 1995; 269: R949-R957.
37. Schwartz MW, Seeley RJ. Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. N Engl J Med 1997; 336: 1802-1811.
38. Frutos MG, Cacicedo L, Fernandez C, Vicent D, Velasco B, Zapatero H et al. Insights into a role of GH secretagogues in reversing the age-related decline in the GH/ IGF-I axis. Am J Physiol Endocrinol Metab 2007; 293: E1140-E1152.
39. Takeda H, Muto S, Hattori T, Sadakane C, Tsuchiya K, Katsurada T et al. Rikkunshito ameliorates the aging-associated decrease in ghrelin receptor reactivity via phosphodiesterase III inhibition. Endocrinology 2010; 151: 244-252.
40. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149: 601-611.
41. White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94: 1198-1206.
42. Sonntag WE, Csiszar A, deCabo R, Ferrucci L, Ungvari Z. Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies. J Gerontol A Biol Sci Med Sci 2012; 67: 587-598.
43. Aksenova MV, Aksenov MY, Carney JM, Butterfield DA. Protein oxidation and enzyme activity decline in old brown Norway rats are reduced by dietary restriction. Mech Ageing Dev 1998; 100: 157-168.
44. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009; 59: 293-315.
45. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y et al. Hypothalamic programming of systemic ageing involving IKK-beta, NF-kappaB and GnRH. Nature 2013; 497: 211-216.
46. Bedard K, Bedard J, Rocheleau G, Ferland G, Gaudreau P. Aging and diets regulate the rat anterior pituitary and hypothalamic transcriptome. Neuroendocrinology 2013; 97: 146-159.
47. Andrews ZB. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci 2011; 34: 31-40.
48. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003; 72: 1154-1161.
49. Maekawa Y, Ohishi M, Ikushima M, Yamamoto K, Yasuda O, Oguro R et al. Klotho protein diminishes endothelial apoptosis and senescence via a mitogen-activated kinase pathway. Geriatr Gerontol Int 2011; 11: 510-516.
50. Csiszar A, Labinskyy N, Jimenez R, Pinto JT, Ballabh P, Losonczy G et al. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech Ageing Dev 2009; 130: 518-527.
51. Du CK, Zhan DY, Morimoto S, Akiyama T, Schwenke DO, Hosoda H et al. Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy. Pharmacol Res Perspect 2014; 2: e00064.
52. Strasser F. Clinical application of ghrelin. Curr Pharm Des 2012; 18: 4800-4812.
53. Wang F, Jiang T, Tang C, Su Z, Zhang N, Li G. Ghrelin reduces rat myocardial calcification induced by nicotine and vitamin D3 in vivo. Int J Mol Med 2011; 28: 513-519.
54. Theil MM, Miyake S, Mizuno M, Tomi C, Croxford JL, Hosoda H et al. Suppression of experimental autoimmune encephalomyelitis by ghrelin. J Immunol 2009; 183: 2859-2866.
55. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430: 686-689.
56. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009; 325: 201-204.
57. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012; 489: 318-321.
58. Ash CE, Merry BJ. The molecular basis by which dietary restricted feeding reduces mitochondrial reactive oxygen species generation. Mech Ageing Dev 2011; 132: 43-54.
59. Speakman JR, Mitchell SE. Caloric restriction. Mol Aspects Med 2011; 32: 159-221.
60. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013; 123: 980-989.